Celltrion Pharm, Inc. (KOSDAQ:068760)

Celltrion Pharm Statistics

Total Valuation

Celltrion Pharm has a market cap or net worth of KRW 2.63 trillion.

Market Cap	2.63T
Enterprise Value	n/a

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Celltrion Pharm has 43.50 million shares outstanding.

Current Share Class	43.50M
Shares Outstanding	43.50M
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.19%
Owned by Insiders (%)	0.18%
Owned by Institutions (%)	3.51%
Float	19.42M

Valuation Ratios

The trailing PE ratio is 101.68.

PE Ratio	101.68
Forward PE	n/a
PS Ratio	9.58
PB Ratio	8.69
P/TBV Ratio	9.83
P/FCF Ratio	n/a
P/OCF Ratio	92.54
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.23, with a Debt / Equity ratio of 0.63.

Current Ratio	1.23
Quick Ratio	0.92
Debt / Equity	0.63
Debt / EBITDA	4.48
Debt / FCF	-87.93
Interest Coverage	6.22

Financial Efficiency

Return on equity (ROE) is 8.91% and return on invested capital (ROIC) is 3.83%.

Return on Equity (ROE)	8.91%
Return on Assets (ROA)	3.41%
Return on Invested Capital (ROIC)	3.83%
Return on Capital Employed (ROCE)	7.92%
Revenue Per Employee	837.59M
Profits Per Employee	79.35M
Employee Count	328
Asset Turnover	0.52
Inventory Turnover	4.20

Taxes

Income Tax	-873.97M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +12.72% in the last 52 weeks. The beta is 1.08, so Celltrion Pharm's price volatility has been similar to the market average.

Beta (5Y)	1.08
52-Week Price Change	+12.72%
50-Day Moving Average	58,152.00
200-Day Moving Average	52,952.75
Relative Strength Index (RSI)	50.05
Average Volume (20 Days)	272,588

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Celltrion Pharm had revenue of KRW 274.73 billion and earned 26.03 billion in profits. Earnings per share was 595.02.

Revenue	274.73B
Gross Profit	80.84B
Operating Income	28.89B
Pretax Income	25.15B
Net Income	26.03B
EBITDA	42.80B
EBIT	28.89B
Earnings Per Share (EPS)	595.02

Balance Sheet

The company has 34.63 billion in cash and 191.75 billion in debt, giving a net cash position of -157.12 billion or -3,612.43 per share.

Cash & Cash Equivalents	34.63B
Total Debt	191.75B
Net Cash	-157.12B
Net Cash Per Share	-3,612.43
Equity (Book Value)	302.75B
Book Value Per Share	6,965.78
Working Capital	48.92B

Cash Flow

In the last 12 months, operating cash flow was 28.44 billion and capital expenditures -30.62 billion, giving a free cash flow of -2.18 billion.

Operating Cash Flow	28.44B
Capital Expenditures	-30.62B
Free Cash Flow	-2.18B
FCF Per Share	-50.14

Margins

Gross margin is 29.43%, with operating and profit margins of 10.51% and 9.47%.

Gross Margin	29.43%
Operating Margin	10.51%
Pretax Margin	9.16%
Profit Margin	9.47%
EBITDA Margin	15.58%
EBIT Margin	10.51%
FCF Margin	n/a

Dividends & Yields

Celltrion Pharm does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.23%
Shareholder Yield	-0.23%
Earnings Yield	0.99%
FCF Yield	-0.08%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on December 27, 2024. It was a forward split with a ratio of 1.05.

Last Split Date	Dec 27, 2024
Split Type	Forward
Split Ratio	1.05

Scores

Celltrion Pharm has an Altman Z-Score of 11.76 and a Piotroski F-Score of 6.

Altman Z-Score	11.76
Piotroski F-Score	6